$PMVP
PMV Pharmaceuticals, Inc.

2021 Q4 Form 10-Q Financial Statement

#000156459021056458 Filed on November 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.305M $5.935M $2.710M
YoY Change 45.95% 119.0%
% of Gross Profit
Research & Development $12.17M $9.162M $5.992M
YoY Change 96.88% 52.9% 22.41%
% of Gross Profit
Depreciation & Amortization $77.00K $80.00K $75.00K
YoY Change 28.33% 6.67% -29.25%
% of Gross Profit
Operating Expenses $18.47M $15.10M $8.701M
YoY Change 75.92% 73.51% 35.11%
Operating Profit -$15.10M -$8.701M
YoY Change 73.51% 35.11%
Interest Expense $106.0K $102.0K $40.00K
YoY Change 112.0% 155.0%
% of Operating Profit
Other Income/Expense, Net $7.000K $105.0K -$60.00K
YoY Change -275.0% -122.06%
Pretax Income -$18.36M -$14.99M -$8.761M
YoY Change 75.68% 71.12% 42.04%
Income Tax $0.00 $19.00K $3.000K
% Of Pretax Income
Net Earnings -$18.36M -$15.01M -$8.764M
YoY Change 75.68% 71.28% 41.93%
Net Earnings / Revenue
Basic Earnings Per Share -$0.33
Diluted Earnings Per Share -$404.4K -$331.4K -$195.7K
COMMON SHARES
Basic Shares Outstanding 45.38M 45.30M
Diluted Shares Outstanding 45.30M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $314.1M $326.3M $373.2M
YoY Change -13.1% -12.58%
Cash & Equivalents $172.5M $176.6M $373.2M
Short-Term Investments $141.6M $149.6M $0.00
Other Short-Term Assets $4.123M $5.904M $500.0K
YoY Change 24.94% 1080.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $301.3M $313.6M $373.7M
YoY Change -17.4% -16.09%
LONG-TERM ASSETS
Property, Plant & Equipment $3.090M $1.394M $573.0K
YoY Change 443.06% 143.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $16.91M $18.60M
YoY Change
Other Assets $221.0K $218.0K $201.0K
YoY Change 9.95% 8.46%
Total Long-Term Assets $30.28M $30.62M $774.0K
YoY Change 3832.73% 3856.46%
TOTAL ASSETS
Total Short-Term Assets $301.3M $313.6M $373.7M
Total Long-Term Assets $30.28M $30.62M $774.0K
Total Assets $331.6M $344.2M $374.4M
YoY Change -9.29% -8.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.189M $1.278M $548.0K
YoY Change 98.44% 133.21%
Accrued Expenses $8.627M $6.740M $4.928M
YoY Change 79.62% 36.77%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.22M $8.563M $5.476M
YoY Change 90.62% 56.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.79M $10.67M
YoY Change
Total Long-Term Liabilities $10.79M $10.67M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $12.22M $8.563M $5.476M
Total Long-Term Liabilities $10.79M $10.67M $0.00
Total Liabilities $23.01M $19.23M $5.476M
YoY Change 258.95% 251.17%
SHAREHOLDERS EQUITY
Retained Earnings -$167.7M -$149.4M -$99.43M
YoY Change 52.64% 50.23%
Common Stock $476.4M $474.3M $468.4M
YoY Change 1.57% 1.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $308.6M $324.9M $369.0M
YoY Change
Total Liabilities & Shareholders Equity $331.6M $344.2M $374.4M
YoY Change -9.29% -8.08%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$18.36M -$15.01M -$8.764M
YoY Change 75.68% 71.28% 41.93%
Depreciation, Depletion And Amortization $77.00K $80.00K $75.00K
YoY Change 28.33% 6.67% -29.25%
Cash From Operating Activities -$12.03M -$12.40M -$7.400M
YoY Change 16.66% 67.54%
INVESTING ACTIVITIES
Capital Expenditures -$262.0K -$501.0K -$40.00K
YoY Change 336.67% 1152.5%
Acquisitions
YoY Change
Other Investing Activities $7.821M -$192.0K $8.080M
YoY Change -102.38%
Cash From Investing Activities $7.559M -$693.0K $8.040M
YoY Change -12698.33% -108.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $223.2M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 295.0K 309.0K 294.5M
YoY Change -121.69% -99.9%
NET CHANGE
Cash From Operating Activities -12.03M -12.40M -7.400M
Cash From Investing Activities 7.559M -693.0K 8.040M
Cash From Financing Activities 295.0K 309.0K 294.5M
Net Change In Cash -4.174M -12.78M 295.1M
YoY Change -64.42% -104.33%
FREE CASH FLOW
Cash From Operating Activities -$12.03M -$12.40M -$7.400M
Capital Expenditures -$262.0K -$501.0K -$40.00K
Free Cash Flow -$11.77M -$11.90M -$7.360M
YoY Change 14.79% 61.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45380354
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y1M13D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M17D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M2D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0035
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0031
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0122
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0151
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7900
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7070
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7990
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7760
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2709000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15495000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6689000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
15097000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
8701000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15097000
us-gaap Operating Income Loss
OperatingIncomeLoss
-39821000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
23000
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-3218129
dei Entity Address Address Line1
EntityAddressAddressLine1
8 Clarke Drive
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6740000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8563000
CY2021Q3 us-gaap Liabilities
Liabilities
19230000
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Bankruptcy Proceedings Reporting Current
EntityBankruptcyProceedingsReportingCurrent
true
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5082000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
361422000
dei Entity Central Index Key
EntityCentralIndexKey
0001699382
CY2021Q3 us-gaap Assets Current
AssetsCurrent
313555000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1394000
CY2021Q3 us-gaap Assets
Assets
344178000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1278000
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
dei Entity Registrant Name
EntityRegistrantName
PMV PHARMACEUTICALS, INC.
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
176641000
CY2021Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
822000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
131010000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3339000
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Document Type
DocumentType
10-Q
CY2020Q4 us-gaap Assets Current
AssetsCurrent
364761000
dei Entity File Number
EntityFileNumber
001-39539
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Trading Symbol
TradingSymbol
PMVP
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
569000
dei Entity Small Business
EntitySmallBusiness
false
dei Document Transition Report
DocumentTransitionReport
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Security12b Title
Security12bTitle
Common stock, par value $0.00001
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 3
dei Entity Address City Or Town
EntityAddressCityOrTown
Cranbury
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08512
dei City Area Code
CityAreaCode
609
dei Local Phone Number
LocalPhoneNumber
642-6670
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
us-gaap Operating Expenses
OperatingExpenses
39821000
us-gaap Operating Expenses
OperatingExpenses
24441000
pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-143000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-60000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
357000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
460000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14992000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8761000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39464000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15011000
pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
14000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
368970000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45352207
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
474301000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149367000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
324948000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
344178000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9162000
CY2020Q4 us-gaap Assets
Assets
365531000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1607000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4803000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
201000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24441000
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
40000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
343000
CY2021Q3 pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
3000
CY2020Q3 pmvp Other Nonoperating Income Expense Other
OtherNonoperatingIncomeExpenseOther
-100000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
105000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8701000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5935000
CY2021Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
18601000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10410000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
218000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
545000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6410000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10667000
CY2020Q4 us-gaap Liabilities
Liabilities
6410000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45352207
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44777818
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44777818
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
469001000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-109880000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
14000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
359121000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
365531000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5992000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24326000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17752000
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
102000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
603000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23981000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8764000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
7000
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-5000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15004000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8769000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.46
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45295232
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6022457
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
us-gaap Net Income Loss
NetIncomeLoss
-39487000
us-gaap Net Income Loss
NetIncomeLoss
-23986000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
14000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39473000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23983000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.88
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.93
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45052100
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4045527
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-70474000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
296000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-7255000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-80000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-77513000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
383000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7967000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
88000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-85009000
CY2020Q3 pmvp Reclassifications Of Temporary To Permanent Equity Shares
ReclassificationsOfTemporaryToPermanentEquityShares
-28188110
CY2020Q3 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
-238723000
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
238723000
CY2020Q3 pmvp Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
194000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
223161000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
670000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8764000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
359121000
CY2021Q1 pmvp Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans
ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
162000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
627000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-11602000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-13000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
348295000
CY2021Q2 pmvp Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans
ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
1256000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1150000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-12874000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
337847000
CY2021Q3 pmvp Exercise Of Stock Options And Common Stock Value Issued Under Employee Stock Purchase Plans
ExerciseOfStockOptionsAndCommonStockValueIssuedUnderEmployeeStockPurchasePlans
309000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1796000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15011000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
324948000
us-gaap Profit Loss
ProfitLoss
-39487000
us-gaap Profit Loss
ProfitLoss
-23986000
us-gaap Share Based Compensation
ShareBasedCompensation
3573000
us-gaap Share Based Compensation
ShareBasedCompensation
1349000
us-gaap Depreciation
Depreciation
230000
us-gaap Depreciation
Depreciation
257000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-459000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-152000
pmvp Other Non Cash Lease Expense
OtherNonCashLeaseExpense
644000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
17000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-144000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
224541000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1743000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-85000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-385000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
42571000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-151143000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27968000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
69790000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2825000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2183000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2397000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34543000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22427000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1087000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
91000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
235167000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
14512000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
85111000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1727000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1727000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
294331000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-183959000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
299872000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
361422000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
73278000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
177463000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
373150000
pmvp Lease Incentives Used For Leasehold Improvements
LeaseIncentivesUsedForLeaseholdImprovements
88000
pmvp Conversion Of Convertible Preferred Stock To Common Stock
ConversionOfConvertiblePreferredStockToCommonStock
238723000
pmvp Conversion Of Warrant Liability To Common Stock
ConversionOfWarrantLiabilityToCommonStock
194000
pmvp Unpaid Offering Costs
UnpaidOfferingCosts
1380000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
23000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
5000
CY2020Q3 pmvp Proceeds From Issuance Of Common Stock Gross
ProceedsFromIssuanceOfCommonStockGross
243536
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
223161
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
5.2651
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15011000
us-gaap Net Income Loss
NetIncomeLoss
-39487000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34543000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149367000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
177463000
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
149611000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:6.05%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.05%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the fair values of common stock, convertible preferred stock and stock-based compensation. Actual results could differ materially from those estimates.</p>
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
174691000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
360041000
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
149611000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
5.2651-for-1 reverse stock split of the Company’s common stock and convertible preferred stock
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
5.2651
CY2021Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
127000
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
6000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
459000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
152000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
822000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
131010000
CY2021Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
18601000
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3185000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2130000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1791000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1561000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1394000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
569000
CY2021Q3 us-gaap Depreciation
Depreciation
80000
CY2020Q3 us-gaap Depreciation
Depreciation
75000
us-gaap Depreciation
Depreciation
230000
us-gaap Depreciation
Depreciation
257000
CY2021Q3 pmvp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3554000
CY2021Q3 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2882000
CY2020Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3109000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
214000
CY2020Q4 pmvp Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
1595000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
90000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
99000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6740000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4803000
CY2018Q3 pmvp Number Of Noncancelable Operating Leases
NumberOfNoncancelableOperatingLeases
2
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
511000
us-gaap Operating Lease Cost
OperatingLeaseCost
1180000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
158000
us-gaap Variable Lease Cost
VariableLeaseCost
470000
CY2021Q3 us-gaap Lease Cost
LeaseCost
669000
us-gaap Lease Cost
LeaseCost
1650000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10410000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
545000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10667000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
11212000
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
us-gaap Operating Lease Payments
OperatingLeasePayments
535000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10314000
CY2021Q3 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsRemainderOfFiscalYear
-264000
CY2021Q3 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueNextTwelveMonths
-2164000
CY2021Q3 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Two
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearTwo
1833000
CY2021Q3 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Three
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearThree
1814000
CY2021Q3 pmvp Lessee Operating Lease Liability Payments Net Of Reimbursements Due Year Four
LesseeOperatingLeaseLiabilityPaymentsNetOfReimbursementsDueYearFour
1869000
CY2021Q3 pmvp Lessee Operating Lease Liability To Be Paid Net Of Repayments After Year Four
LesseeOperatingLeaseLiabilityToBePaidNetOfRepaymentsAfterYearFour
13402000
CY2021Q3 pmvp Lessee Operating Lease Liability Payments Net Of Repayments Due
LesseeOperatingLeaseLiabilityPaymentsNetOfRepaymentsDue
16490000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5278000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
11212000
CY2021Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
511000
CY2020Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
118000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1180000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
444000
CY2021Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
0
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45352207
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45352207
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44777818
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44777818
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Dividends Common Stock
DividendsCommonStock
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
537803
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4609725
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4090970
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.14
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
238792000
pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
715380
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
715380
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
30.03
pmvp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantForfeituresInPeriod
43117
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
43117
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.77
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.17
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
3699920
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4225430
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.78
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
94079000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4225430
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.78
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
94079000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2574442
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.91
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
69247000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
15952000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1796000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
670000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3573000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1349000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-15011000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8764000
us-gaap Net Income Loss
NetIncomeLoss
-39487000
us-gaap Net Income Loss
NetIncomeLoss
-23986000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45295232
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6022457
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45052100
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4045527
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.46
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.88
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.93

Files In Submission

Name View Source Status
0001564590-21-056458-index-headers.html Edgar Link pending
0001564590-21-056458-index.html Edgar Link pending
0001564590-21-056458.txt Edgar Link pending
0001564590-21-056458-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pmvp-10q_20210930.htm Edgar Link pending
pmvp-10q_20210930_htm.xml Edgar Link completed
pmvp-20210930.xsd Edgar Link pending
pmvp-20210930_cal.xml Edgar Link unprocessable
pmvp-20210930_def.xml Edgar Link unprocessable
pmvp-20210930_lab.xml Edgar Link unprocessable
pmvp-20210930_pre.xml Edgar Link unprocessable
pmvp-ex311_8.htm Edgar Link pending
pmvp-ex312_6.htm Edgar Link pending
pmvp-ex321_7.htm Edgar Link pending
pmvp-ex322_9.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending